Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response

Phase 2

• Conditions: Recurrent Ovarian Cancer; Cancer - Ovarian and primary peritoneal

• Registration Number: ACTRN12608000013369
• Lead Sponsor: Royal Women's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-01-10
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 37

Inclusion Criteria

Rising CA125 (Rustin)
2 previous lines of chemotherapy

Exclusion Criteria

Impending bowel obstruction

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumour response (Recist criteria)[18 months];CA125 response as measured in peripheral blood.Gynaecological Cancer Intergroup criteria[2 weeks following last of 3 treatment cycles]

Secondary Outcome Measures

Name	Time	Method
Survival[18 months];Progression free survival[At 6 months following trial completion]